The RRPV Roundup

RRPV Members, 

We’re excited to share the latest edition of our biannual e-newsletter, The RRPV Roundup! Each issue is designed to keep you updated on key milestones, highlight members, and share relevant opportunities across the consortium.

Also, we’d love to hear from you. Please take a few minutes to complete our annual membership survey—your feedback helps us understand what’s working well and where we can do even better. Click here to share your input today. Responses are due by Wed., Oct. 15 at 11:59 p.m. ET.

Thank you for being a valued member of the consortium. We look forward to keeping you informed and connected!

Consortium Updates

• We hosted our Annual General Membership Meeting in Washington, D.C., on Aug. 26–27, bringing together industry members and representatives from BARDA. With 385 attendees, the event was a tremendous success thanks to your energy, participation, and enthusiasm. Check out some photos from the event below.
• Our team exhibited at the World Vaccine Congress in Washington, D.C., alongside the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) and Medical CBRN Defense Consortium (MCDC). We also exhibited at the BIO International Convention in Boston, MA, with the BioMaP-Consortium, MCDC, and Advanced Technology International. Take a look at the snapshots from our time at the events below.
• We awarded five projects in FY25— learn more about the awards here.
  
• In FY25, RRPV welcomed 182 new members: 145 small businesses, 11 academic institutions, 10 non-profits, and 16 large businesses. See the full list of current members here.

General Membership Meeting Photos

Conference Photos

Upcoming Opportunities

New Focus Area 

Below are some upcoming opportunities to keep on your radar. Be sure to visit our Opportunities webpage for additional details, and watch for email announcements to stay up to date.

• Assay development for Superior Understanding of Response and Efficacy (ASSURE)
• Rapid Antibody Production for Immunoassay Development (RAPID) -  RFI
• Agnostic Diagnostics

We’ve added a new focus area to the consortium—the Medical Countermeasure Clinical Research Centers (MCCRCs)—to provide end-to-end clinical trial capabilities, from study design and execution to data analysis and regulatory submissions. By leveraging innovative trial designs, real-world evidence, and advanced technologies, MCCRCs accelerate the development of vaccines, therapeutics, diagnostics, and devices for CBRN threats, pandemic influenza, and emerging infectious diseases.

Members' Spotlight

We’re excited to feature a members’ spotlight in most of our biannual e-newsletters. This is a special opportunity to get to know the incredible organizations that make up our consortium and the value they bring. For our first-ever spotlight, we are featuring Sapphiros and Unicorn Biotechnologies. Read a highlight of the spotlights below. To be considered for future features in our newsletter or social media content, fill out our form here!

Read an excerpt of Unicorn Biotechnologies' spotlight below and view the full profile here.

Q: What does your company do? What specific capabilities or strengths does your company offer?

A: Our core capabilities are:

1. Developing/providing instrumentation to automate cell culture workflows (e.g., for
   bioassays).
2. Weird & wonderful contract research projects. If you have a nasty technical problem in cellular biology, molecular engineering, bioprocess engineering, sensor development, or lab automation/instrumentation, give us a call. We will work tirelessly to help solve the problems that most CROs won’t touch with a ten-foot pole.

Unicorn Biotechnologies has three technologies/products of relevance to the RRPV community:

1. Intelligent bench-top instruments to automate & scale cell culture workflows.
2. Contract cellular & molecular biology work (from construct engineering to
   bioassay development).
3. Acting as a tech integrator & tester (e.g., building self-driving labs, streamlining LNP delivery/tox assays, etc.).

Reach out to us at hello@unicornb.io, we’d love to speak!

Learn more about Unicorn Biotechnologies here. 

Read a preview of Sapphiros' spotlight below and view the full profile here.

Q: What trends or innovations do you foresee shaping the future of the industry, and how is your company preparing for those changes?

A: We see a continued movement away from centralized lab testing toward rapid, at-home, near-patient diagnostics that are affordable, accurate, easy to use, and connected.

Our next-generation diagnostics focus on fit-for-purpose, engineered for their intended use, user, and setting. Our platforms are built on modularity, where, depending on the setting, an ultra-low-cost lateral flow test might be sufficient, while a more connected device with printed electronics and the ability to transfer data off-board may fit the needs of a different setting.

By controlling the diagnostic supply chain through manufacturing all critical proteins, primers, and probes in our molecular assays, we can offer accurate diagnostics at a low cost of goods, ultimately ensuring that diagnostics are accessible to everyone. This vertical integration ensures quality and resilience and allows us agility to respond to new health threats and global diagnostic needs.

Learn more about Sapphiros here. 

Events of Interest to RRPV Members

BARDA Accelerator

Network Showcase 

Oct. 15, 2025 | 12:30-7 p.m. |

The Foundry | Cambridge, MA

Join the BARDA Accelerator Network (BAN) Showcase, featuring exciting innovations and breakthrough technologies from the portfolios of every BAN Hub.

New Member Orientation and RRPV 101 Training  

Oct. 30, 2025 | Virtual

Join RRPV to gain a deeper understanding of the consortium, explore strategies to maximize the value of your membership, discover new opportunities for collaboration, and learn how to actively engage in shaping the future of medical countermeasure innovation.

BARDA Innovation Symposium

Nov. 20, 2025 | BARDA Headquarters | Washington, DC

Join BARDA to connect with early-stage companies, government agencies, funders, investors, and strategic partners driving the next generation of medical countermeasures.

Resources

Below is a list of recommended consortium- and government-based resources for you to explore. Be sure to take full advantage of them!

• govmates: Innovation Resource Hub
• Collaboration Database - Log in to the Members-Only website, which can be accessed via the RRPV website.
• TechWatch - Submit your meeting request for an opportunity to connect with U.S. government experts to discuss your product, technology, or capabilities, and explore potential partnership opportunities.
• BARDA Target Product Profiles (TPP) - Strategic planning tool used to define the ideal characteristics of therapeutic, vaccine, diagnostic, and device candidates of interest to BARDA. 
• Interested in teaming with another RRPV Member Organization for a current or upcoming RPP? Send us a capabilities profile and we will post it on the RRPV Teaming board on the Members-Only website, which can be accessed via the 
  RRPV website.